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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S118related musculoskeletal disorder. Autophagy is an essential cellular
homeostasis mechanism that is responsible for removal of dysfunctional
macromolecules and organelles. Aging-associated or experimental defects
in autophagy contribute to organismal and tissue-speciﬁc aging while
enhancement of autophagy may protect against certain aging related
pathologies such as OA and extend lifespan in model organisms. The
objective of this study was to determine whether glucosamine (GlcN),
a dietary supplement that is safe and has shown beneﬁcial effects in
cellular and animal models of joint health, can activate autophagy in vitro
and in vivo.
Methods: Chondrocytes from normal human articular cartilage were
treated with GlcN (0.1-10 mM). Autophagy and mTOR activation was
analyzed by Western blotting and quantiﬁcation of LC3, a main marker of
autophagy activation and phosphorylation levels of ribosomal protein S6
(prbS6), a downstream target of mTOR. Transgenic reporter mice with
green ﬂuorescent protein fused to the autophagy marker LC3 (GFP-LC3
mice) were treated with GlcN (250 mg/kg weight/day) for 7 days.
Autophagy activation and mTOR signaling were analyzed by confocal
microscopy and inmunohistochemistry.
Results: In vitro studies: we investigated the effect of GlcN on autophagy
activation by quantiﬁcation the levels of LC3-II in normal human chon-
drocytes. The results indicated an increase of LC3-II expression after GlcN
treatment at 4 and 24 hours. To determine whether GlcN regulates the
mTOR signaling pathway, we evaluated the prbs6. The results indicated
a reduction of prbs6 after GlcN treatment in a time dependent manner at 4
and 24 hours, indicating that autophagy activation by GlcN, associated
with modulation of a second main signaling event that is mediated by
mTOR inhibition. In vivo studies: we analyzed in vivo effect of GlcN on
autophagy using GFP-LC3 mice. Oral administration of GlcN led to
a marked activation of autophagy in liver. In addition, in knee articular
cartilage and menisci, there was a decrease in prbS6 expression.
Conclusions: GlcN modulates several components of the mTOR and
autophagy pathway in vitro and in vivo. These ﬁndings suggest that GlcN is
an effective autophagy activator and motivate future studies on its efﬁcacy
in modifying aging-related cellular changes and supporting joint health.>
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IDENTIFICATION OF AN EXTRACELULAR O-N-ACETYL-GLYCOSYLASE
RESPONSIBLE FOR AN INCREASED LEVEL OF O-LINKED N-
ACETYLGLUCOSAMINE MODIFIED PROTEINS IN THE CARTILAGE OF
PATIENTS WITH OSTEOARTHRITIS.
G. Herrero-Beaumont 1, L. Tardío 1, J. Andrés-Bergós 1, E. Gómez-
Barrena 2, R. Largo 1. 1 IIS-Fundacion Jimenez Diaz, Madrid, Spain; 2Hosp.
Univ.rio La Paz, Madrid, Spain
Purpose:: The modiﬁcation of serine/threonine residues on cytoplasmic
and nuclear proteins by O-linked N-acetylglucosamine (O-GlcNAc) is
a post-translational modiﬁcation that has been implicated in the regula-
tion of many different signal transduction pathways. Although O-GlcNAc
modiﬁcation has been involved in the pathophysiology of different
degenerative and age-related diseases, such as Alzheimer or diabetes, its
role in OA remains unknown. O-GlcNAc transferase (OGT) and O-GlcNA-
case are the intracellular enzymes responsible for the level of O-GlcNA-
cylated proteins. The goals of this study were: (1) to determine the amount
O-GlcNAcylated proteins in the cartilage of OA patients in comparison to
cartilage from healthy donors and (2) to localize the presence of OGT in the
cartilage of these patients.
Methods: Human OA cartilage was isolated from the knee of patients
during joint replacement surgery (n¼8), while healthy cartilage was
obtained from the knee of age and sex-matched healthy donors (n¼8). To
carry out further protein expression studies, chondrocytes were isolated
by sequential protease digestion. Additional cartilage fragments were
immediately frozen or ﬁxed to be embedded in parafﬁn. The level of
O-GlcNAcylation, OGT and O-GlcNAcase expression were assessed by
western blot analysis employing speciﬁc antibodies. Furthermore OGT
expression was localized by immunohistochemical techniques.
Results: The amount of O-GlcNAcylated proteins was signiﬁcantly
increased in human OA cartilage compared to that of healthy cartilage
(approx. 4.5 fold, p<0.05). So, human knee OA was characterized by the
accumulation of different O-GlcNAc modiﬁed proteins. We also observedan increased expression of the short and long isoforms of OGT in the
cartilage of OA patients in comparison with healthy donors (short OGT:
0.19+0.03 vs. 0.002+0.003, p<0.05; long OGT: 0.10+0.03 vs. 0.049+0.008).
A prevalence of the short isoform was found in the analysis of OGT in
human total cartilage, while a predominant expression of the long isoform
was noted in OA chondrocytes (short OGT: 0.21+0.04 vs. 0.014+0.008,
p<0.05; long OGT: 0.48+0.09 vs. 0.13+0.07, p<0.05). Unexpectedly,
immunohistochemical studies revealed the presence of OGT both in the
cartilage matrix and within cells. We observed a clear increase in the
pericellular OGT signal in OA patients and an in the chondrocyte clones,
while a diffuse OGT presence was noted in healthy donors. Regarding O-
GlcNAcase presence, we observed a decrease in the expression of the long
isoform of this enzyme in the OA cartilage and an increased presence of the
short isoform in comparison to healthy cartilage samples (long O-GlcNA-
case: 0.09+0.02 vs. 0.214+0.07, p<0.05; short O-GlcNAcase: 2.59+0.30 vs.
0.04+0.03,p<0.05).
Conclusions: These results demonstrate that OA could be associated with
a deregulation in the hexosamine biosynthesis pathway that could lead to
an accumulation of O-GlcNAcylated proteins in the cartilage, mainly due to
an increased OGT presence. Our data would link OA pathophysiology to
alterations in key glucose sensor pathways, and support the hypothesis
that O-GlcNAc modiﬁcation may play an important role in the develop-
ment of chronic and age-related diseases.
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P21 REGULATES MMP-13 EXPRESSION AND DECREASED AGGRECAN
EXPRESSION VIA STAT3/ SDF-1 PATHWAY.
H. Shinya, T. Nishiyama, T. Fujishiro, S. Hashimoto, K. Kawakita, K. Iwasa,
S. Sakata, R. Kuroda, M. Kurosaka. Kobe Univ., Kobe, Japan
[Purpose]The cyclin-dependent kinase inhibitor p21 was initially identi-
ﬁed as a potent inhibitor of cell cycle progression. Recently, p21 was
identiﬁed as not just a CKI, but also an important transcriptional regulator.
p21 has been shown to regulate the activity of NF-kB, c-Myc, C/EBP, E2F
and STAT3. Olive et al. reported that p21 activity was essential for the
regulation of cell proliferation and inﬂammation after arterial injury in
local vascular cells. Further, p21 regulated the expression of SDF-1 and
MMP-13. These molecules are believed to be onset of osteoarthritis (OA) in
articular cartilage. We previously presented that p21 mRNA expression
was down-regulated in OA chondrocytes compared with normal chon-
drocytes. In this study, we evaluated the function of p21 in response to
cyclical stretch stress.
[Methods]Cyclical stretch stress was introduced to human normal chon-
drocytes (NHAC-kn; cell line derived from human normal chondrocyte) for
24h (0.25 Hz) by using STREX (Osaka Japan). Chondrocytes were treated
with p21 siRNA by lipofection method, and cyclical stretch stress was
introduced. Col2, aggrecan, MMPs, SDF-1 mRNA expressions were
analyzed by realtime PCR and phosphorylation of STAT3 was analyzed by
western blotting. Pull down assay was performed to conﬁrm binding p21
and STAT3. Chondrocytes were treated with p21 siRNA and cyclical stretch
stress was introduced to chondrocytes with treatment of STAT3 speciﬁc
inhibitor. Aggrecan, MMP13, SDF-1 mRNA expressions were analyzed by
realtime PCR. Finally, soluble glycosaminoglycan concentrations (sGAG)/
cell were analyzed after cyclical stretch stress.
[Results]Expression levels of p21, col2 and aggrecan were increased at 5%
stretch stress, but decreased at 10% stress. Expression levels of MMP3, 13
were increased at 5% stress (ﬁg 1). The expression levels of MMP-13 were
increased by p21siRNA transfection after 5% stress (ﬁg 2). However, the
expression levels of aggrecan were decreased (ﬁg 2). Phosphorylation of
STAT 3 was up-regulated by down-regulation of p21 expression (Fig3a).
SDF-1 expression was up-regulated by down-regulation of p21 expression
(Fig3b). Pull down assay showed that p21 bound to STAT3 (Fig3c). MMP13
and SDF-1 expressions were up-regulated by p21 down-regulation, but
decreased by STAT3 inhibitor (Fig4). Cell number was increased by p21
down-regulation. Total sGAG and sGAG/cell were decreased (Fig5).
[Conclusion]Down-regulation of p21 increased MMP-13 expression and
decreased aggrecan expression via STAT3/ SDF-1 pathway. Cell prolifera-
tion was increased by p21 down-regulation, but total matrix syntheses
were decreased. P21 may contribute to maintain homeostasis in normal
cartilage.
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IDENTIFYING THE KEY ENZYMES INVOLVED IN MATRIPTASE-INDUCED
CARTILAGE AGGRECAN AND COLLAGEN RESORPTION
D.J. Wilkinson, D. Rowan, J. Milner. Musculoskeletal Res. Group, Newcastle
upon Tyne, United Kingdom
Purpose: Serine proteases interact with the matrix metalloproteases
(MMPs) in the cascades leading to the proteolytic degradation of cartilage
that occurs in osteoarthritis (OA). We have previously identiﬁed elevated
expression of the type II transmembrane serine protease, matriptase, in OA
cartilage and shown that it is an initiator of cartilage collagen resorption
via the induction and activation of proMMPs. The aim of this study was to
further investigate the mechanism of action of matriptase in inducing
cartilage resorption by measuring temporal expression of both MMPs and
A Disintegrin and Metalloprotease with Thrombospondin Repeats (ADAM
TS) in matriptase-induced resorbing cartilage. Furthermore, we investigate
the role of matriptase in the breakdown of aggrecan, the most abundant
proteoglycan in cartilage. We also describe in vitro analysis of a potent
inhibitor of matriptase.
Methods: Human OA cartilage in explant culture was stimulated with
recombinant matriptase. Collagen and proteoglycan breakdown were
assessed by analysing the levels of hydroxyproline and glycosaminoglycan
(GAG), respectively. For gene expression studies, RNA was extracted from
cartilage explant culture, reverse transcribed and real-time PCR was per-
formed. Active collagenase levels were determined using H3 collagen in
a bioassay format. MMP1 and MMP13 were measured by ELISA. In order to
determine if matriptase could directly degrade cartilage proteoglycan,
cartilage was freeze-thawed prior to stimulation. Conditionedmedia taken
from stimulated explant culture was used for western blotting. These blots
were probed with antibodies speciﬁc for neo-epitopes generated by MMP
or aggrecanase degraded aggrecan (BC-14 and BC-3, respectively). Kinetic
analysis of a matriptase inhibitor towards matriptase and other serine
proteases were monitored using the synthetic ﬂuorogenic substrate Boc-
QAR-AMC, in a standard ﬂuorometer and analysed using GraphPad Prism 5
software.
Results: Here we demonstrate that matriptase causes a rapid induction of
MMP1, MMP13 and to a lesser extent ADAM TS4 gene expression. This
correlates with a gradual increase in active collagenase levels, MMP-1 and
MMP-13 and the subsequent breakdown of proteoglycan and collagen. The
addition of matriptase to freeze-thawed cartilage did not induce proteo-
glycan resorption demonstrating that matriptase does not directly degrade
this matrix component. Matriptase-induced proteoglycan breakdown is
metalloprotease dependent as the addition of GM6001, a metalloprotease
inhibitor completely blocked resorption. Neoepitope antibodies directed
towards MMP and aggrecanase cleavage revealed that MMP activity is
largely responsible for this proteoglycan breakdown. In vitro analysis of
